

## Special Issue

# Antibiotic Therapy for *Clostridioides difficile* Infections

### Message from the Guest Editors

The increase in *Clostridioides difficile* infection (CDI) cases during the past 2 decades has played a major role in the advancement of antimicrobial stewardship programs. CDI rates are often the focus of many antimicrobial- and syndrome-specific interventions deployed by ASPs. However, despite ASP and infection control efforts, CDI remains a problematic, opportunistic infection. Recent guideline updates from leading national and international expert panels have occurred with the advent of new therapeutics and evolving data. This Special Issue will seek manuscripts on ASP interventions that may impact CDI, therapeutic approaches to CDI, and additional healthcare-related research on CDI management including education, access, and more.

### Guest Editors

Dr. P. Brandon Bookstaver

College of Pharmacy, University of South Carolina, Columbia, SC 29208, USA

Prof. Dr. Christopher M. Bland

College of Pharmacy, University of Georgia, Savannah, GA 31405, USA

### Deadline for manuscript submissions

closed (31 December 2022)



## Antibiotics

an Open Access Journal  
by MDPI

Impact Factor 4.6  
CiteScore 8.7  
Indexed in PubMed



[mdpi.com/si/92971](https://mdpi.com/si/92971)

*Antibiotics*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[antibiotics@mdpi.com](mailto:antibiotics@mdpi.com)

[mdpi.com/journal/  
antibiotics](https://mdpi.com/journal/antibiotics)





# Antibiotics

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.6  
CiteScore 8.7  
Indexed in PubMed



[mdpi.com/journal/  
antibiotics](https://mdpi.com/journal/antibiotics)



## About the Journal

### Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

---

### Editor-in-Chief

Prof. Dr. Nicholas Dixon  
School of Chemistry and Molecular Bioscience, University of  
Wollongong, Wollongong, NSW 2522, Australia

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)